Medical School · Year 3 · Internal Medicine · includes a quiz and discussion video

Seminar 06: Hypertension Management

Year 3: Internal Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Define hypertension and describe current classification
2. Differentiate primary from secondary hypertension
3. Describe initial evaluation of the hypertensive patient
4. Explain treatment goals and first-line therapies
5. Apply pharmacotherapy principles to patient scenarios
6. Recognize and manage hypertensive emergencies

Seminar Outline

I. Definition and Classification

The 2017 American College of Cardiology and American Heart Association guidelines define hypertension using lower thresholds than previous classifications, reflecting evidence that cardiovascular risk begins to increase at blood pressures previously considered normal. Normal blood pressure is defined as systolic pressure below 120 mmHg and diastolic pressure below 80 mmHg. Elevated blood pressure encompasses systolic readings of 120-129 mmHg with diastolic below 80 mmHg, representing a category that warrants lifestyle intervention to prevent progression. Stage 1 hypertension is defined as systolic pressure of 130-139 mmHg or diastolic pressure of 80-89 mmHg, while Stage 2 hypertension includes systolic pressure of 140 mmHg or higher or diastolic of 90 mmHg or higher.

Accurate blood pressure measurement requires attention to proper technique, as incorrect measurement is a common source of misdiagnosis and inappropriate treatment. Patients should rest quietly for at least 5 minutes before measurement, seated with feet flat on the floor, back supported, and arm supported at heart level. An appropriately sized cuff is essential, with the bladder encircling at least 80% of the arm circumference; an undersized cuff falsely elevates readings. The average of at least 2 readings taken 1 minute apart should be recorded, and both arms should be measured initially with the higher reading used for subsequent monitoring.

Out-of-office blood pressure monitoring plays an increasingly important role in confirming the diagnosis and guiding treatment decisions. Home blood pressure monitoring allows patients to measure their pressure in a more natural environment, with measurements taken twice daily (morning and evening) before medications and meals. Ambulatory blood pressure monitoring provides comprehensive 24-hour data including nocturnal pressures and is particularly useful for evaluating suspected white coat or masked hypertension. Diagnostic thresholds differ for out-of-office measurements, with daytime ambulatory averages above 130/80 mmHg and nighttime averages above 120/70 mmHg considered elevated.

White coat hypertension and masked hypertension represent important clinical phenomena that affect management decisions. White coat hypertension occurs when office blood pressure is elevated but out-of-office measurements are normal, affecting 15-30% of patients with elevated office readings. While historically considered benign, recent evidence suggests white coat hypertension carries some cardiovascular risk compared to true normotension. Masked hypertension, the opposite phenomenon with normal office but elevated out-of-office readings, may carry even greater risk because it often goes undetected and untreated. Both conditions are best identified through home monitoring or ambulatory blood pressure monitoring.

<image>Panel A: ACC/AHA blood pressure classification chart showing normal, elevated, stage 1 hypertension, and stage 2 hypertension categories with corresponding systolic and diastolic thresholds. Panel B: Step-by-step illustration of proper blood pressure measurement technique including patient positioning, cuff placement, and measurement protocol. Panel C: Comparison of office versus out-of-office blood pressure measurements showing diagnostic thresholds for each method. Panel D: Diagram explaining white coat hypertension and masked hypertension with their clinical implications and management approaches.</image>

II. Epidemiology and Pathophysiology

Hypertension affects approximately 47% of adults in the United States under current diagnostic criteria, making it one of the most prevalent chronic conditions. Despite widespread awareness, treatment, and control efforts, only about 25% of hypertensive patients achieve blood pressure targets. The prevalence increases dramatically with age, affecting over 70% of individuals aged 65 and older. Cardiovascular risk doubles for each 20 mmHg increase in systolic or 10 mmHg increase in diastolic blood pressure above optimal levels, even within ranges previously considered normal.

The pathophysiology of hypertension involves complex interactions between cardiac output, peripheral vascular resistance, and regulatory mechanisms. Blood pressure is determined by the equation BP = cardiac output x peripheral vascular resistance, with cardiac output influenced by heart rate, contractility, and intravascular volume. The renin-angiotensin-aldosterone system plays a central role through effects on vasoconstriction, sodium retention, and vascular remodeling. Sympathetic nervous system activity increases heart rate, contractility, and vascular tone, while endothelial dysfunction with reduced nitric oxide availability contributes to increased vascular resistance.

Risk factors for developing hypertension include both modifiable and non-modifiable characteristics. Age and family history represent non-modifiable factors, with hypertension developing in most individuals by age 70-75 if they live long enough. Black individuals have higher prevalence, earlier onset, and greater severity of hypertension compared to other racial groups, with increased rates of target organ damage. Modifiable risk factors include obesity, physical inactivity, excessive sodium intake, inadequate potassium intake, excessive alcohol consumption, and obstructive sleep apnea. Addressing modifiable risk factors through lifestyle intervention can prevent hypertension in at-risk individuals and reduce blood pressure in those already affected.

Sustained hypertension causes progressive target organ damage affecting the heart, brain, kidneys, eyes, and vasculature. Cardiac manifestations include left ventricular hypertrophy, coronary artery disease, and heart failure, with LVH detectable on ECG in 10-30% and echocardiography in 30-50% of hypertensive patients. Cerebrovascular effects include increased risk of ischemic and hemorrhagic stroke, transient ischemic attacks, and cognitive decline. Chronic kidney disease results from nephrosclerosis with progressive decline in GFR and proteinuria. Hypertensive retinopathy progresses through stages of arteriolar narrowing, arteriovenous nicking, hemorrhages, and exudates to papilledema in severe cases.

<image>Panel A: Diagram showing the determinants of blood pressure including cardiac output components (heart rate, contractility, preload) and peripheral resistance factors with regulatory mechanisms. Panel B: Illustration of the renin-angiotensin-aldosterone system showing the cascade from renin release through angiotensin II effects and aldosterone action. Panel C: Bar graph demonstrating the prevalence of hypertension by age, sex, and race/ethnicity in the United States. Panel D: Target organ damage illustration showing effects of chronic hypertension on the heart (LVH), brain (stroke, cognitive decline), kidney (nephrosclerosis), and eye (retinopathy).</image>

III. Initial Evaluation

The initial evaluation of a patient with elevated blood pressure serves multiple important purposes that guide subsequent management. First, the diagnosis must be confirmed through repeated measurements and ideally out-of-office assessment to exclude white coat hypertension. Cardiovascular risk assessment using validated tools such as the Pooled Cohort Equations helps determine treatment thresholds and intensity. Identification of target organ damage influences prognosis and treatment urgency. Screening for secondary causes is essential, particularly in patients with features suggesting an underlying etiology.

A thorough history should explore multiple domains relevant to hypertension management. Duration of elevated blood pressure and previous treatments including medications tried, responses, and reasons for discontinuation provide valuable context. Symptoms suggesting target organ damage include chest pain, dyspnea, visual changes, neurologic symptoms, and claudication. Cardiovascular risk factors including diabetes, dyslipidemia, smoking, family history of premature cardiovascular disease, and physical inactivity should be assessed. Medications that may elevate blood pressure include NSAIDs, decongestants, oral contraceptives, corticosteroids, and certain herbal supplements.

Physical examination findings help assess severity, identify complications, and screen for secondary causes. Accurate blood pressure measurement in both arms establishes the baseline and identifies asymmetry suggesting aortic coarctation or subclavian stenosis. Fundoscopic examination reveals arteriolar narrowing, arteriovenous nicking, hemorrhages, exudates, or papilledema indicating hypertensive retinopathy severity. Cardiovascular examination may reveal murmurs (aortic regurgitation from dilated aorta), S4 gallop (decreased ventricular compliance), or displaced apical impulse (LVH or dilation). Abdominal examination should include auscultation for renal artery bruits suggesting renovascular hypertension.

Initial laboratory testing provides essential information for risk stratification and identification of secondary causes or complications. A basic metabolic panel reveals electrolyte abnormalities (hypokalemia suggesting aldosteronism), renal function impairment, and glucose abnormalities. Urinalysis screens for proteinuria indicating kidney involvement. Lipid panel completes cardiovascular risk assessment. Electrocardiogram may reveal left ventricular hypertrophy, prior myocardial infarction, or arrhythmias including atrial fibrillation. Additional testing including echocardiography, urinary albumin-to-creatinine ratio, or screening for secondary causes depends on clinical findings and initial results.

<image>Panel A: Comprehensive flowchart showing the goals of initial hypertension evaluation including diagnosis confirmation, risk assessment, target organ damage assessment, and secondary cause screening. Panel B: Key history elements organized by category including blood pressure history, symptoms of complications, cardiovascular risk factors, and medication review. Panel C: Physical examination findings relevant to hypertension with their clinical significance, including fundoscopic changes and cardiovascular findings. Panel D: Initial laboratory testing algorithm showing essential tests for all patients and additional tests based on clinical indications.</image>

IV. Secondary Hypertension

Secondary hypertension, caused by an identifiable underlying condition, accounts for approximately 5-10% of hypertensive patients but is important to recognize because treatment of the underlying cause may cure or significantly improve blood pressure control. Clinical features that increase suspicion for secondary causes include onset before age 30 without obesity or family history, severe hypertension at diagnosis, resistant hypertension despite three or more medications including a diuretic, sudden worsening of previously controlled blood pressure, and presence of specific symptoms or signs suggesting underlying disorders.

Primary aldosteronism is now recognized as far more common than previously believed, affecting 5-15% of hypertensive patients and an even higher proportion of those with resistant hypertension. Classically presenting with hypertension and hypokalemia, many patients have normal potassium levels, so screening should not depend on hypokalemia. The aldosterone-to-renin ratio exceeding 30 with aldosterone above 15 ng/dL serves as the screening test, with confirmatory testing through salt loading or other suppression tests. Subtypes include aldosterone-producing adenoma, treated surgically, and bilateral adrenal hyperplasia, managed with mineralocorticoid receptor antagonists.

Renovascular hypertension results from renal artery stenosis, most commonly due to atherosclerosis in older patients or fibromuscular dysplasia in younger women. Clinical clues include severe hypertension with renal insufficiency, flash pulmonary edema, significant blood pressure elevation after starting ACE inhibitors or ARBs, asymmetric kidney size, and abdominal bruits. Diagnostic imaging includes renal artery duplex ultrasonography, CT angiography, or MR angiography. While medical therapy is usually preferred for atherosclerotic disease, revascularization may be considered for refractory hypertension or declining renal function in carefully selected patients.

Obstructive sleep apnea is likely the most common secondary cause of hypertension, present in approximately 30-50% of hypertensive patients. Repetitive episodes of apnea cause intermittent hypoxemia and sympathetic activation that persists during waking hours. Clinical features include snoring, witnessed apneas, daytime somnolence, obesity, and large neck circumference. The STOP-BANG questionnaire provides a validated screening tool. Treatment with continuous positive airway pressure can modestly reduce blood pressure and significantly improves other cardiovascular outcomes. Additional secondary causes include pheochromocytoma (episodic symptoms, catecholamine excess), Cushing syndrome (clinical features of glucocorticoid excess), thyroid disorders, and coarctation of the aorta.

<image>Panel A: Clinical features suggesting secondary hypertension including age of onset, severity, resistance to treatment, and specific symptoms organized by suspected etiology. Panel B: Prevalence of different secondary causes in the general hypertensive population and in those with resistant hypertension. Panel C: Diagnostic algorithm for primary aldosteronism showing screening with aldosterone-to-renin ratio, confirmatory testing, and subtype differentiation. Panel D: Clinical clues and diagnostic approach for renovascular hypertension with imaging modality comparison.</image>

V. Treatment Goals

Current guidelines recommend a blood pressure target of less than 130/80 mmHg for most adults with hypertension, based on evidence that more intensive treatment reduces cardiovascular events. This target applies broadly to patients with established cardiovascular disease, diabetes mellitus, chronic kidney disease, and calculated 10-year ASCVD risk of 10% or greater. For elderly patients aged 65 and older, a systolic blood pressure target below 130 mmHg is recommended if tolerated, acknowledging the need to monitor for orthostatic hypotension and other adverse effects. In patients with very high baseline risk, the absolute benefit of achieving lower targets is greatest.

The decision to initiate pharmacologic therapy depends on both blood pressure level and overall cardiovascular risk. For patients with stage 1 hypertension (130-139/80-89 mmHg), medication is recommended if 10-year ASCVD risk is 10% or greater, if established cardiovascular disease is present, or if diabetes or CKD exists. For stage 1 hypertension with lower cardiovascular risk, an initial 3-6 month trial of lifestyle modification alone is reasonable. Stage 2 hypertension (above 140/90 mmHg) warrants prompt initiation of pharmacotherapy along with lifestyle modification regardless of calculated risk.

Lifestyle modifications represent the foundation of hypertension management and can significantly lower blood pressure, sometimes sufficiently to achieve targets without medication. The DASH diet emphasizing fruits, vegetables, whole grains, and low-fat dairy while limiting saturated fat and sodium can reduce systolic blood pressure by 8-14 mmHg. Sodium restriction to less than 2.3 grams daily (ideally less than 1.5 grams) provides 5-6 mmHg reduction. Regular aerobic physical activity of at least 150 minutes weekly at moderate intensity lowers pressure by 4-9 mmHg. Weight loss of approximately 1 mmHg per kilogram lost and limiting alcohol to no more than two drinks daily for men and one for women provide additional benefit.

Cardiovascular risk reduction extends beyond blood pressure control to comprehensive risk factor management. Statin therapy is indicated for most patients with diabetes aged 40-75 and those with 10-year ASCVD risk exceeding 7.5%. Aspirin is no longer routinely recommended for primary prevention due to increased bleeding risk but remains appropriate for secondary prevention. Smoking cessation dramatically reduces cardiovascular risk and should be addressed at every visit. Blood glucose management in diabetic patients and lipid optimization complement blood pressure control to maximize cardiovascular risk reduction.

<image>Panel A: Blood pressure treatment targets for different patient populations including general adults, elderly patients, and those with specific comorbidities. Panel B: Algorithm for determining when to initiate pharmacotherapy based on blood pressure stage and cardiovascular risk level. Panel C: Quantified blood pressure reductions achievable with each lifestyle modification including DASH diet, sodium restriction, exercise, and weight loss. Panel D: Comprehensive cardiovascular risk management framework showing integration of blood pressure control with lipid management, glucose control, and lifestyle factors.</image>

VI. Pharmacologic Treatment

Four classes of antihypertensive medications are recommended as first-line therapy, with selection guided by individual patient characteristics and comorbidities. Thiazide-type diuretics, particularly chlorthalidone and indapamide, are effective, inexpensive, and have extensive outcome data supporting their use. ACE inhibitors provide excellent efficacy with additional benefits in patients with heart failure, post-myocardial infarction, diabetes with proteinuria, and chronic kidney disease. ARBs offer similar efficacy and benefits to ACE inhibitors with lower incidence of cough, making them appropriate alternatives when ACE inhibitors are not tolerated. Dihydropyridine calcium channel blockers such as amlodipine effectively lower blood pressure and are particularly useful in combination regimens.

Drug selection should be guided by compelling indications related to comorbid conditions when present. Heart failure with reduced ejection fraction benefits from ACE inhibitors or ARBs (or ARNI), beta-blockers (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonists, and diuretics. Patients with prior myocardial infarction should receive ACE inhibitors and beta-blockers. Diabetic patients with proteinuria or chronic kidney disease benefit from ACE inhibitors or ARBs due to their renoprotective effects beyond blood pressure reduction. In Black patients, thiazide diuretics and calcium channel blockers are more effective as initial monotherapy than ACE inhibitors or ARBs, though RAAS inhibitors remain appropriate when combined with other agents or when compelling indications exist.

Combination therapy is often necessary to achieve blood pressure targets, with most patients requiring two or more medications. When initial blood pressure is more than 20/10 mmHg above goal, starting with two-drug combination therapy is more effective and achieves control faster than sequential monotherapy. Effective combinations include ACE inhibitor or ARB combined with calcium channel blocker, and ACE inhibitor or ARB combined with thiazide diuretic. ACE inhibitors and ARBs should never be combined due to increased adverse effects without additional benefit. Fixed-dose combination pills improve adherence and should be utilized when possible.

Each drug class has characteristic side effects that influence selection and monitoring. Thiazide diuretics can cause hypokalemia, hyperuricemia, and modest increases in glucose; potassium levels should be monitored. ACE inhibitors cause dry cough in approximately 10% of patients and rarely angioedema; both classes cause hyperkalemia, particularly in patients with CKD. Dihydropyridine calcium channel blockers commonly cause peripheral edema that is not responsive to diuretics. Beta-blockers, while no longer considered first-line for uncomplicated hypertension, remain important for specific indications but may cause fatigue, bradycardia, and bronchospasm in susceptible individuals.

<image>Panel A: First-line antihypertensive drug classes with mechanisms of action, typical blood pressure reduction, and key characteristics. Panel B: Compelling indications for specific drug classes based on comorbid conditions including heart failure, prior MI, CKD, and diabetes. Panel C: Preferred two-drug combinations showing synergistic pairings and combinations to avoid. Panel D: Common side effects of each drug class with monitoring recommendations.</image>

VII. Resistant Hypertension

Resistant hypertension is defined as blood pressure remaining above goal despite treatment with three antihypertensive medications at optimal doses, including a diuretic, or blood pressure controlled on four or more medications. True resistant hypertension must be distinguished from apparent resistance due to pseudo-resistance. This condition affects approximately 10-15% of treated hypertensive patients and is associated with significantly increased cardiovascular risk. Proper identification and management of resistant hypertension is essential to reduce this excess risk.

Pseudo-resistance is more common than true resistant hypertension and must be excluded through systematic evaluation. Medication nonadherence is the most frequent cause, affecting up to 50% of patients with apparent resistant hypertension; direct assessment through drug levels or witnessed dosing may be necessary. White coat effect, where office blood pressure exceeds true blood pressure, should be assessed through home or ambulatory monitoring. Suboptimal medication regimens including inadequate diuretic therapy, inappropriate drug combinations, or subtherapeutic doses contribute to apparent resistance. Improper measurement technique, particularly undersized cuff in obese patients, causes falsely elevated readings.

Once pseudo-resistance is excluded, evaluation for secondary causes and contributing factors should be thorough. Primary aldosteronism is present in 15-20% of patients with resistant hypertension and should be screened with aldosterone-to-renin ratio. Obstructive sleep apnea is highly prevalent and polysomnography should be considered in appropriate patients. Lifestyle factors including high sodium intake, obesity, excessive alcohol, and use of blood pressure-elevating medications or substances must be addressed. Chronic kidney disease both contributes to and results from resistant hypertension, often requiring higher doses of loop diuretics.

Management of confirmed resistant hypertension involves optimization of the existing regimen and addition of fourth-line agents. Ensuring adequate diuretic therapy is essential; chlorthalidone is preferred over hydrochlorothiazide for its longer duration and greater efficacy, and loop diuretics may be necessary for patients with reduced GFR. Spironolactone at 25-50 mg daily has demonstrated particular efficacy as add-on therapy in resistant hypertension, likely due to the high prevalence of aldosterone excess in this population. Alternative fourth-line options include other mineralocorticoid receptor antagonists, beta-blockers, alpha-blockers, or direct vasodilators. Referral to a hypertension specialist is appropriate for patients who remain uncontrolled despite optimization.

<image>Panel A: Definition and diagnostic criteria for resistant hypertension distinguishing true resistance from controlled resistant hypertension. Panel B: Systematic approach to excluding pseudo-resistance including medication adherence assessment, out-of-office blood pressure measurement, and regimen optimization. Panel C: Evaluation algorithm for secondary causes in resistant hypertension with particular emphasis on primary aldosteronism and obstructive sleep apnea. Panel D: Management approach including diuretic optimization, fourth-line agent selection with evidence for spironolactone, and criteria for specialist referral.</image>

VIII. Special Populations

Elderly patients present unique considerations in hypertension management, balancing the substantial benefits of treatment against increased susceptibility to adverse effects. Isolated systolic hypertension, where systolic pressure is elevated with normal or low diastolic pressure, is the predominant hypertension pattern in older adults and reflects arterial stiffening. A systolic blood pressure target below 130 mmHg is recommended if tolerated, but standing blood pressure must be assessed to screen for orthostatic hypotension. Starting with lower medication doses and titrating more slowly reduces the risk of adverse effects. Frailty and life expectancy should be considered when setting individualized treatment goals.

Black patients experience higher prevalence, earlier onset, and more severe target organ damage from hypertension compared to other groups. Lower plasma renin activity in Black populations results in diminished response to ACE inhibitors and ARBs as monotherapy. Thiazide diuretics and calcium channel blockers are more effective initial agents and should be preferentially selected. When compelling indications for RAAS inhibition exist or when combined with diuretics or calcium channel blockers, ACE inhibitors and ARBs remain effective. Sodium sensitivity is often more pronounced, making sodium restriction particularly beneficial.

Chronic kidney disease creates a bidirectional relationship with hypertension, where elevated blood pressure accelerates CKD progression while impaired renal function contributes to hypertension. A blood pressure target below 130/80 mmHg is recommended for CKD patients, with even lower targets potentially beneficial for those with significant proteinuria. ACE inhibitors or ARBs are preferred for their renoprotective effects, particularly in patients with albuminuria. Loop diuretics become necessary as GFR declines below 30 mL/min/1.73m2, since thiazides become less effective. Careful monitoring of potassium and creatinine is essential, with modest creatinine elevations up to 30% acceptable after RAAS inhibitor initiation.

Patients with diabetes mellitus have a blood pressure target below 130/80 mmHg given their elevated cardiovascular risk. ACE inhibitors or ARBs should be first-line therapy, particularly for patients with albuminuria where they slow progression of diabetic kidney disease. SGLT2 inhibitors provide additional blood pressure reduction of 3-6 mmHg and offer cardiovascular and renal benefits independent of glucose lowering. Combining ACE inhibitors or ARBs with calcium channel blockers or thiazides achieves targets in most diabetic patients. Orthostatic hypotension from autonomic neuropathy may complicate treatment and requires monitoring.

<image>Panel A: Age-specific considerations in hypertension management showing treatment benefits, targets, and precautions for elderly patients. Panel B: Racial differences in hypertension pathophysiology with preferred initial therapy choices for Black patients. Panel C: Hypertension management in chronic kidney disease showing the bidirectional relationship, treatment targets, and medication selection by GFR stage. Panel D: Integrated approach to hypertension in diabetes including blood pressure targets, preferred medications, and adjunctive therapies.</image>

IX. Hypertensive Crisis

Hypertensive crisis encompasses severe blood pressure elevation, typically systolic above 180 mmHg and/or diastolic above 120 mmHg, and is subdivided based on the presence or absence of acute target organ damage. Hypertensive urgency refers to severe elevation without evidence of acute organ damage, while hypertensive emergency indicates severe elevation with acute, ongoing target organ injury. This distinction is critical because it determines the setting, pace, and method of blood pressure reduction. Approximately 1-2% of hypertensive patients will experience a hypertensive crisis during their lifetime.

Hypertensive emergencies manifest as acute damage to susceptible organ systems and require immediate evaluation and treatment. Neurologic emergencies include hypertensive encephalopathy presenting with headache, confusion, visual disturbances, and potentially seizures; ischemic stroke; and intracerebral or subarachnoid hemorrhage. Cardiovascular emergencies include acute coronary syndrome, acute heart failure with pulmonary edema, and aortic dissection. Renal manifestations include acute kidney injury with oliguria and rising creatinine. Severe hypertensive retinopathy with papilledema, hemorrhages, and exudates indicates end-organ damage. Eclampsia represents a pregnancy-specific hypertensive emergency requiring urgent delivery.

Management of hypertensive emergency requires intravenous antihypertensive therapy with careful monitoring, typically in an intensive care setting. The general goal is to reduce mean arterial pressure by approximately 25% within the first hour, then gradually toward 160/100 mmHg over the next 2-6 hours, avoiding precipitous drops that could cause ischemia. Specific targets vary by condition: aortic dissection requires aggressive reduction to systolic below 120 mmHg within 20 minutes, while ischemic stroke management is more permissive to maintain cerebral perfusion. First-line intravenous agents include nicardipine, a titratable calcium channel blocker; labetalol, combining alpha and beta blockade; and clevidipine, an ultra-short-acting calcium channel blocker.

Hypertensive urgency, characterized by severe elevation without acute organ damage, can generally be managed with oral medications and does not require hospitalization in most cases. The goal is gradual blood pressure reduction over 24-48 hours rather than rapid lowering. Reinstitution or intensification of oral antihypertensive therapy is appropriate, often with an additional agent or increased doses of existing medications. Patient education regarding medication adherence is essential, as many urgencies result from nonadherence. Close outpatient follow-up within 1-2 weeks ensures adequate blood pressure control and allows further therapy adjustment.

<image>Panel A: Classification of hypertensive crisis distinguishing urgency from emergency based on target organ damage assessment. Panel B: Target organ manifestations of hypertensive emergency organized by system including neurologic, cardiovascular, renal, and ophthalmologic findings. Panel C: Blood pressure reduction goals in hypertensive emergency showing general approach and condition-specific targets for aortic dissection, stroke, and other emergencies. Panel D: Intravenous antihypertensive agents with onset of action, mechanism, and preferred indications for each.</image>

X. Monitoring and Follow-Up

Initial follow-up after starting or changing antihypertensive therapy should occur within one month to assess blood pressure response, medication tolerability, and need for adjustment. Blood pressure typically reaches steady state within 2-4 weeks of initiating or changing therapy, making this an appropriate interval for titration decisions. If blood pressure remains above goal, the dose should be increased or an additional agent added. Once blood pressure is at target, follow-up can be extended to every 3-6 months for stable patients.

Monitoring for adverse effects guides safe long-term therapy and medication adjustments. Electrolytes and renal function should be checked within 1-2 weeks of starting or adjusting ACE inhibitors, ARBs, or diuretics, then periodically thereafter. Potassium elevation with ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists requires monitoring and possible dose reduction or discontinuation. Thiazide diuretics may cause hypokalemia, hyponatremia, and modest increases in glucose and uric acid. Calcium channel blockers should be assessed for peripheral edema, which may require dose reduction or discontinuation.

Medication adherence is essential for blood pressure control, yet approximately 50% of patients discontinue antihypertensive medications within the first year. Strategies to improve adherence include simplifying regimens through once-daily dosing and fixed-dose combination pills, addressing cost concerns through generic substitution, and engaging patients in shared decision-making about treatment goals. Home blood pressure monitoring engages patients in their care and provides valuable data for treatment decisions. Regular follow-up visits provide opportunities to reinforce the importance of blood pressure control and address barriers to adherence.

Long-term management requires ongoing attention to lifestyle factors, periodic reassessment of cardiovascular risk, and surveillance for target organ damage. Lifestyle counseling regarding diet, exercise, weight management, and sodium restriction should be reinforced at every visit. Periodic assessment of renal function, urinary albumin excretion, and electrocardiogram allows detection of target organ progression. As patients age or develop new comorbidities, medication regimens may need adjustment, and treatment goals should be periodically reconsidered. Annual comprehensive cardiovascular risk assessment ensures appropriate intensity of risk factor management.

<image>Panel A: Follow-up schedule showing recommended visit intervals for initial treatment, titration phase, and stable maintenance, with activities at each visit type. Panel B: Laboratory monitoring recommendations for each drug class showing timing of initial and follow-up testing. Panel C: Strategies to improve medication adherence including regimen simplification, patient engagement, and addressing barriers. Panel D: Long-term management framework showing integration of blood pressure monitoring, lifestyle reinforcement, and surveillance for target organ damage.</image>

Summary

• Hypertension is defined as systolic blood pressure of 130 mmHg or higher or diastolic of 80 mmHg or higher per ACC/AHA 2017 guidelines
• Proper measurement technique is essential; confirm diagnosis with out-of-office readings when possible
• Primary (essential) hypertension accounts for 90-95% of cases; screen for secondary causes if clinical features suggest
• Blood pressure target is less than 130/80 mmHg for most patients including those with diabetes, CKD, and established CVD
• First-line medications include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers
• Drug selection should be guided by compelling indications: ACE inhibitors or ARBs for heart failure, post-MI, diabetes with proteinuria, and CKD
• Thiazides and calcium channel blockers are more effective initial therapy in Black patients
• Resistant hypertension requires exclusion of pseudo-resistance, evaluation for secondary causes, and optimized diuretic therapy with spironolactone often effective
• Hypertensive emergency involves acute target organ damage and requires IV therapy; urgency can be managed with oral agents
• Regular monitoring of blood pressure, electrolytes, and renal function guides safe and effective long-term therapy

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown